State of New Jersey Common Pension Fund D Grows Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

State of New Jersey Common Pension Fund D grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 73,259 shares of the biopharmaceutical company’s stock after purchasing an additional 1,674 shares during the quarter. State of New Jersey Common Pension Fund D owned approximately 0.06% of Alnylam Pharmaceuticals worth $14,023,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its stake in shares of Alnylam Pharmaceuticals by 6.0% during the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after purchasing an additional 364,021 shares during the last quarter. abrdn plc grew its position in shares of Alnylam Pharmaceuticals by 910.7% in the 4th quarter. abrdn plc now owns 232,716 shares of the biopharmaceutical company’s stock worth $44,544,000 after buying an additional 209,691 shares during the last quarter. Royal London Asset Management Ltd. raised its stake in shares of Alnylam Pharmaceuticals by 86.7% during the 3rd quarter. Royal London Asset Management Ltd. now owns 306,595 shares of the biopharmaceutical company’s stock worth $54,303,000 after acquiring an additional 142,357 shares in the last quarter. Federated Hermes Inc. purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $26,250,000. Finally, TD Asset Management Inc lifted its position in Alnylam Pharmaceuticals by 38.0% during the third quarter. TD Asset Management Inc now owns 495,364 shares of the biopharmaceutical company’s stock valued at $87,729,000 after acquiring an additional 136,283 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on ALNY shares. BMO Capital Markets restated an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. Wolfe Research initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. Citigroup cut their price objective on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Finally, Wells Fargo & Company cut their price objective on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research note on Friday, February 16th. Nine investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $216.12.

Alnylam Pharmaceuticals Trading Down 0.1 %

ALNY traded down $0.09 during midday trading on Thursday, hitting $143.71. 489,263 shares of the company traded hands, compared to its average volume of 780,202. The company has a market capitalization of $18.10 billion, a price-to-earnings ratio of -40.05 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $218.88. The business has a 50 day simple moving average of $150.36 and a two-hundred day simple moving average of $166.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. The business’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the business posted ($1.68) earnings per share. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.46 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.